Program EADA 2021
The program on 18 November consists of 3 building blocks. Registration for lectures in one or more of the various blocks is now open:
I: Setting the scene: Corporates, Authorities & globally active Organisations
II: Technology and Product Updates in AMR: Academia, Start-ups & SMEs
III: Accelerating AMR R&D: Initiatives to boost national / global AMR R&D
| CET | I: SETTING THE SCENE OF AMR R&D | |
|---|---|---|
| 09:30 _____ | Antimicrobial resistance (AMR): global threat and innovative solutions Dr Maarten van Dongen; AMR Insights (Netherlands) | |
| 10:00 _____ | Global coordination of R&D and priority settings to fight AMR Dr Valeria Gigante; World Health Organisation (CH) | |
| 10:20 _____ | iiCON: Delivering Solutions for Integrated Solutions in AMR Prof Janet Hemingway; Liverpool School of Tropical Medicine (UK) | |
| 10:40 _____ | – Coffee break – | |
| 11:00 _____ | JPIAMR: Global collaborative platform supporting transnational research Dr Shawon Lahiri; JPIAMR (Sweden/EU) | |
| 11:20 _____ | Fighting antibiotic resistance, today and tomorrow Dr Colin Garner; Antibiotic Research UK (UK) | |
| 11:40 _____ | Alternative approaches to antibiotics in fighting AMR Dr Maneesh Paul; Acharya Institutes (India) | |
| 12:00 _____ | New antibiotics to patients by 2030: partnering to create market conditions that enable sustainable investment in the antibiotic pipeline Dr Martin Heidecker; AMR action fund | |
| 12:20 _____ | Concluding remarks on the morning program Dr Maarten van Dongen; AMR Insights (Netherlands) | |
| 12:35 _____ | – Lunch break – | |
| II: TECHNOLOGY AND PRODUCT UPDATES IN AMR | ||
| 01:00 _____ | Novel LpxA inhibitors targeting Pseudomonas aeruginosa Dr Alastair Parkes; Evotec (UK) | |
| 01:20 _____ | Next Generation Anti-Infectives To Fight Global Anti-Microbial Resistance Leonie de Best; Madam Therapeutics (Netherlands) | |
| 01:40 _____ | Two exciting late stage clinical assets and a range of earlier research programmes Dr Bill Love; Destiny Pharma (UK) | |
| 02:00 _____ | Tears hold a possibility to fight ABR Dr Richard Stead; Qures Goup (UK) | |
| 02:20 _____ | A rapid, low cost, antibiotic susceptibility test for urinary tract infections Dr Stuart Hannah; University of Strathclyde/ Microplate Dx (UK) | |
| 02:40 _____ | Novel non-pharmaceutical approach to prevent and control of bacterial infections without giving rise to AMR Dr Vipula Tailor: Sonix Medical Devices, Inc (USA) | |
| 03:00 _____ | Reconsidering current academic approaches in antibiotics medicinal chemistry, cases studies Dr Yves Janin; CNRS-Institut Pasteur (France) | |
| 03:20 _____ | Predicting antimicrobial susceptibility directly from blood using whole-genome sequencing Dr Melis Anahtar, MD; Day Zero Diagnostics (USA) | |
| 03:40 _____ | Fighting MDR Neisseria gonorrhoeae with novel massive polypharmacology Dr Pascal Mayer: Alphanosos (France) | |
| 03:50 _____ | – Coffee break – | |
| III: ACCELERATING AMR R&D | ||
| 04:00 _____ | Supporting innovators to fight drug-resistant bacterial infections Douglas Haggstrom; INCATE (Switzerland) | |
| 04:20 _____ | Global AMR R&D Hub: Catalysing the transition from evidence to global AMR policy decisions Dr Satya Dash; Global AMR R&D Hub (Germany) | |
| 04:40 _____ | Creating a large collection of chemical matter specifically targeting Gram-negative antimicrobial drug discovery Dr Bruce Blough; CC4CARB / NIH NIAID (USA) | |
| 05:00 _____ | Delivering drug and/or diagnostic in the areas of Neglected Diseases Dr Shridhar Narayanan; Foundation for Neglected Disease Research (India) | |
| 05:10 _____ | Fostering AMR R&D in India, for India and beyond Dr Taslimarif Saiyed; C-CAMP (India) | |
| 05:20 _____ | The role of Diagnostics in the fight against AMR, the LMICs perspective Dr Cecilia Ferreyra; FIND (Switzerland ) | |
| 05:40 _____ | ILSE: a unique model to accelerate early innovation in AMR Dr Thomas Richardson, ILSE (USA) | |
| 05:50 _____ | Closing remarks Dr Maarten van Dongen; AMR Insights (Netherlands) | |
| 06:00 _____ | … | – Closure – |
